Global biopharmaceutical contract manufacturing market was estimated to be worth roughly US$ 8.4 billion in 2021 and is expected to grow at a CAGR of 10.5% to reach US$ 18.7 billion by 2029. Reduced overall time to market investment in new drugs, access to expensive technologies, and greater flexibility are some advantages offered by biopharmaceutical …